<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03518944</url>
  </required_header>
  <id_info>
    <org_study_id>NFEC-2017-197</org_study_id>
    <nct_id>NCT03518944</nct_id>
  </id_info>
  <brief_title>Establishing of an Early Warming System of Premature Ovarian Insufficiency</brief_title>
  <official_title>Establishing of an Early Warming System of Premature Ovarian Insufficiency</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Premature ovarian insufficiency (POI) is a clinical syndrome defined by loss of ovarian
      activity before the age of 40 years. The POI guideline development group of ESHRE recommends
      the following diagnostic criteria: oligo/ amenorrhea for at least 4 months and an elevated
      follicle stimulating hormone (FSH) level ＞25 mIU/mL on two occasion ＞4 weeks apart. Some
      clinicians and researchers proposed that POI was a progressive disease and there were three
      stages of POI: occult POI, biochemical POI, overt POI. However, there is lack of reliable
      indicators to assess the different stages of POI. The present study is to explore the change
      of menstruation condition, basal follicle-stimulating hormone, anti-müllerian hormone and
      antral follicle count during the development of POI, and whether those marks can assess the
      different stages of POI.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2017</start_date>
  <completion_date type="Anticipated">July 1, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>3 Years</target_duration>
  <primary_outcome>
    <measure>the change of serum follicle-stimulating hormone levels</measure>
    <time_frame>Every 3 months from date of recruit until the date of study completion, assessed up to 48 months</time_frame>
    <description>the serum FSH levels between day 2 to day 5 of menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of menstruation situation</measure>
    <time_frame>Every 3 months from date of recruit until the date of study completion, assessed up to 48 months</time_frame>
    <description>Menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of serum anti-mullerian hormone levels</measure>
    <time_frame>Every 3 months from date of recruit until the date of study completion, assessed up to 48 months</time_frame>
    <description>the serum anti-mullerian hormone levels between day 2 to day 5 of menstrual cycle</description>
  </primary_outcome>
  <primary_outcome>
    <measure>the change of antral follicle count</measure>
    <time_frame>Every 3 months from date of recruit until the date of study completion, assessed up to 48 months</time_frame>
    <description>Antral follicle count between day 2 to day 5 of menstrual cycle</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Primary Ovarian Insufficiency</condition>
  <arm_group>
    <arm_group_label>occult premature ovarian insufficiency</arm_group_label>
    <description>Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two occasion ＞4 weeks apart</description>
  </arm_group>
  <biospec_retention>Samples Without DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      blood plasma
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        patients of occult premature ovarian insufficiency
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Serum FSH levels ≥10mIU/ml/ serum AMH levels ≤1.0pg/ml/ AFC ≤5, on at least two
             occasion ＞4 weeks apart

        Exclusion Criteria:

          -  Polycystic Ovarian Syndrome

          -  other causes of amenorrhea
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shiling Chen, M.D./Ph.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Shiling Chen, M.D./Ph.D.</last_name>
    <phone>+86-020-62787604</phone>
    <email>chensl_92@163.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Center for Reproductive Medicine, Department of Gynecology and Obstetrics, Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shi-Ling Chen, M.D., Ph.D.</last_name>
      <phone>+86-20-62787604</phone>
      <email>chensl_92@163.com</email>
    </contact>
    <investigator>
      <last_name>Shi-Ling Chen, M.D., Ph.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>European Society for Human Reproduction and Embryology (ESHRE) Guideline Group on POI, Webber L, Davies M, Anderson R, Bartlett J, Braat D, Cartwright B, Cifkova R, de Muinck Keizer-Schrama S, Hogervorst E, Janse F, Liao L, Vlaisavljevic V, Zillikens C, Vermeulen N. ESHRE Guideline: management of women with premature ovarian insufficiency. Hum Reprod. 2016 May;31(5):926-37. doi: 10.1093/humrep/dew027. Epub 2016 Mar 22.</citation>
    <PMID>27008889</PMID>
  </reference>
  <reference>
    <citation>Welt CK. Primary ovarian insufficiency: a more accurate term for premature ovarian failure. Clin Endocrinol (Oxf). 2008 Apr;68(4):499-509. Epub 2007 Oct 29. Review.</citation>
    <PMID>17970776</PMID>
  </reference>
  <verification_date>August 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>March 28, 2018</study_first_submitted>
  <study_first_submitted_qc>April 25, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 8, 2018</study_first_posted>
  <last_update_submitted>April 25, 2018</last_update_submitted>
  <last_update_submitted_qc>April 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 8, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Primary Ovarian Insufficiency</mesh_term>
    <mesh_term>Menopause, Premature</mesh_term>
    <mesh_term>Gonadal Dysgenesis</mesh_term>
    <mesh_term>Turner Syndrome</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

